Key facts
- This page summarizes Robert Peter Kadlec's Form 4 filing for MiNK Therapeutics, Inc. (INKT).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 09 Dec 2024, 16:10.
Robert Peter Kadlec - 30 Oct 2024 Form 4 Insider Report for MiNK Therapeutics, Inc. (INKT)
- Reporting relationship
- Director
- Issuer ticker
- INKT
- Reported as of
- 30 Oct 2024
- Net transaction value
- +$8,969
- SEC form
- 4
- Accepted by SEC
- 09 Dec 2024, 16:10:04 UTC
- Next SEC filing
- 05 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/Christine Klaskin, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Robert Peter Kadlec filed Form 4 for MiNK Therapeutics, Inc. (INKT) on 09 Dec 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: +$8,969.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
INKT
transaction
Common Stock
Award
- Transaction value
- $8,969
- Shares
- +12,286
- Change %
- Price
- $0.7300
- Shares after
- 12,286
- Date
- 01 Dec 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INKT
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +41,745
- Change %
- Price
- $0.000000
- Shares after
- 41,745
- Date
- 30 Oct 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 41,745
- Exercise price
- $0.7200
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Stock Options were awarded in accordance with the MiNK Therapeutics Inc. 2021 Amended and Restated Equity Incentive Plan on October 30, 2024 and will vest in three equal annual installments on each of October 30, 2025, 2026 and 2027 (provided Dr. Kadlec maintains a service relationship with the company through each such vesting date).
Footnote F2
Dr. Kadlec was granted restricted stock unites ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.